News Bayer files finerenone in EU for heart failure Bayer has filed its mineralocorticoid receptor antagonist finerenone as a treatment heart failure in the EU, but can it meet blockbuster sales hopes?
News Large study points to benefits - and risks - of GLP-1 drugs The largest observational study of GLP-1 weight-loss drugs suggests their benefits could be wide-ranging, but there are some risks to consider.
News Novo Nordisk swells alliance with AI firm Valo Health Novo Nordisk almost doubles the scale of its R&D alliance with AI specialist Valo Health, which now spans 20 programmes and a value of up to $4.6bn.
News Safety fear halts Keros PAH trial dosing, hitting its shares An unexpected side effect has led Keros to halt dosing in two arms of its phase 2 trial of pulmonary arterial hypertension drug cibotercept.
News FDA kicks off review of Cytokinetics' aficamten for HCM Cytokinetics should hear back from the FDA next September about its application for Camzyos rival aficamten in obstructive hypertrophic cardiomyopathy
News MSD adds rocket fuel to Winrevair's engine in PAH ZENITH trial of MSD's Winrevair in PAH could add further momentum to an already impressive launch
News Pharma in a spin as it tries to gauge Trump tariffs impact Pharmaceuticals are exempt from the tariffs revealed by President Donald Trump, for now, but the industry is bracing for what may come next.
Sales & Marketing Sponsored Health Trends 2025: Reimagining What's Possible Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl